And EpiCongress will place you right at the heart of the action…
With more epigenetics focused companies than anywhere else, the epicenter for epigenetic drug developers is returning to Boston this July 23 - 26.
The meeting has been designed in collaboration with thought leaders at GSK, EpiZyme, Constellation, Pfizer, Genentech, Celgene, Abbvie, Gilead, Acetylon, and many more. EpiCongress will not only help you to understand the basic mechanisms behind genome regulation and chromatin function. It will also address the most pressing clinical considerations to ensure the success of current and future candidates.
Hear from 50 expert speakers from across pharma, biotechs and research institutes presenting their most promising data. Capture the last 12 months of progress by hearing how epigenetic candidates have been performing across the board. And access the translational science with the potential to transform your drug discovery.
With over 30 industry presentations and pharma packed discussions, covering everything from target discovery to patient selection, choose the presentations which are most applicable to your research. Take the time to explore what’s on offer throughout the streams to build your personalized 2 day itinerary.
Attend the FUNDAMENTAL EPIGENETICS stream to:
Get the latest from the EPIGENTIC INNOVATIONS stream:
Take part in the discussions during the EPIGENETICS IN THE CLINIC stream to:
Make the most out of your time at EpiCongress by taking part in the pre and post conference workshops. These sessions offer you the chance to bring your own questions to the table to discuss solutions with your peers in a more open and informal format. Choose from the selection of individual workshops or attend all four...
A: Epigenomics Data Management and Visualization Strategies
Led by Charles Epstein, Program Manager, The Broad Institute of Harvard & MIT
B: Bridging Epigenetic Mechanisms and Stem Cell Biology
Led by Zhong Wang, Assistant Professor of Medicine, Massachusetts General Hospital
C: Translating Epigenetic Regulation to Clinical Candidates
Led by Daniel Vitt, CSO, 4SC & Hella Kohlhof, Manager, Translation Pharmacology, 4SC
Who should attend?
Chief Executive Officer
Chief Scientific Officer
Vice President, Head of Chemistry,
Director, Translational Medicine,
Cancer Epigenetics DPU
HealthCare Ventures & CEO,
Shape Therapeutics & Tensha Therapeutics
"The panel discussions should be fun, but I think I am most excited about hearing Paul Marks, he is such an important figure in the development of therapeutics in this field" Nessa Carey, Pfizer
"I am looking forward to many presentations, with a special interest in the biology of histone methyltransferases and histone demethylases, as well as progress being made in developing inhibitors of these enzymes." James Barsoum, RaNA Therapeutics
"The companies advancing toward IND and clinic (Constellation, GSK, Epizyme..)" Emmanuel Normant, Constellation Pharmaceuticals
"Difficult question: My interest span across all the streams, but Epigenetic innovation will be the one." Emmanuel Normant, Constellation Pharmaceuticals
"Both the Fundamental Epigenetics as well as the Epigenetic Innovation streams offer very interesting presentations." Peter Staller, EpiTherapeutics
"I plan on cloning myself and attending all of them. If that does not work, then I will mostly attend Epigenetics in the Clinic." John Pilon, Cetya Therapeutics
"Really looking forward to coming back this year, seeing some familiar faces and meeting the exciting new speakers for fascinating discussions. It's going to be Epic!" Nessa Carey Epigenetic Lead, External Research & Development Innovation Unit, Pfizer
"EpiCongress is an outstanding conference and again it looks to be a highlight in the epigenetics world as it has been from its inauguration on" EnVivo Pharmaceuticals